Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

128.11
-0.0400-0.03%
Post-market: 128.250.1400+0.11%19:00 EDT
Volume:2.99M
Turnover:383.09M
Market Cap:8.29B
PE:-52.22
High:128.28
Open:128.24
Low:128.06
Close:128.15
Loading ...

Blueprint Medicines Corporation Conducted Annual Stockholders Meeting

Reuters
·
20 Jun

Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129

MT Newswires Live
·
17 Jun

Barclays Sticks to Their Hold Rating for Blueprint Medicines (BPMC)

TIPRANKS
·
13 Jun

Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT

TIPRANKS
·
13 Jun

Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses

Reuters
·
13 Jun

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term Ayvakit®/Ayvakyt® (Avapritinib) Treatment at 2025 Eha and Eaaci Congresses

THOMSON REUTERS
·
13 Jun

Review -- Barron's

Dow Jones
·
07 Jun

Blueprint Medicines’ CSO Makes a Significant Stock Sale!

TIPRANKS
·
06 Jun

Chief Scientific Officer Percy H. Carter Reports Disposal of Common Shares of Blueprint Medicines Corporation

Reuters
·
06 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle

Reuters
·
06 Jun

BUZZ-UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal

Reuters
·
06 Jun

UBS Adjusts Price Target on Blueprint Medicines to $129 From $88, Maintains Neutral Rating

MT Newswires Live
·
05 Jun

Blueprint Medicines Is Maintained at Neutral by UBS

Dow Jones
·
05 Jun

Sanofi’s Strategic Acquisition of Blueprint Medicines: A Boost to Rare Disease Portfolio and Long-term Growth

TIPRANKS
·
05 Jun

Leerink Partners Sticks to Their Hold Rating for Blueprint Medicines (BPMC)

TIPRANKS
·
05 Jun

Blueprint Medicines Corp : Guggenheim Cuts to Neutral From Buy

THOMSON REUTERS
·
04 Jun

Blueprint Medicines upgraded to Neutral from Sell at Citi

TIPRANKS
·
04 Jun

Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132

MT Newswires Live
·
03 Jun

Blueprint Medicines Cut to Market Perform From Market Outperform by JMP Securities

Dow Jones
·
03 Jun

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), Blueprint Medicines (BPMC) and Vera Therapeutics (VERA)

TIPRANKS
·
03 Jun